The ECDC, the EFSA and the EMA have for the first time jointly explored associations between consumption of antimicrobials in humans and food-producing animals, and antimicrobial resistance in bacteria from humans and food-producing animals, using 2011 and 2012 data currently available from their re...levant five EU monitoring networks. Combined data on antimicrobial consumption and corresponding resistance in animals and humans for EU MSs and reporting countries were analysed using logistic regression models for selected combinations of bacteria and antimicrobials. A summary indicator of the proportion of resistant bacteria in the main food-producing animal species was calculated for the analysis, as consumption data in food-producing animals were not available at the species level
more
Response strategy for South Sudan to Covid-19 pandemic
BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379
Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE...COVERY and REMAP-CAP randomised controlled trials triggered this guideline update, resulting in a strong recommendation for interleukin-6 (IL-6) receptor blockers (tocilizumab or sarilumab) in patients with severe or critical covid-19.
Prior recommendations: (a) A recommendation not to use ivermectin in patients with covid-19, regardless of disease severity, except in the context of a clinical trial; (b) a strong recommendation against the use of hydroxychloroquine in patients with covid-19, regardless of disease severity; (c) a strong recommendation against the use of lopinavir-ritonavir in patients with covid-19, regardless of disease severity; (d) a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19; (e) a conditional recommendation against systemic corticosteroids in patients with non-severe covid-19; and (f) a conditional recommendation against remdesivir in hospitalised patients with covid-19.
more
A formulary of dermatological preparations and background information on therapeutic choices, production and dispensing. 2nd edition
World Health Organization Department of Reproductive Health and Research
Brocher Foundation, Hermance, Geneva, Switzerland, 27–29 April 2016
Guidelines for national programmes and other stakeholders, for annexes see http://www.who.int/tb/publications/2012/tb_hiv_policy_9789241503006/en/
This document aims to assist policy‑makers, health care providers and researchers to understand key concepts in health ethics and to identify basic ethical questions surrounding health and health care. It illustrates the challenges of applying ethical principles to global public health and outline...s practical strategies for dealing with those challenges.
more
This document offers public health guidance for the prevention and control of COVID-19 in reception centres, and other temporary accommodation facilities, in the context of the mass influx of Ukrainian people into the European Union (EU), the European Economic Area (EEA) and the Republic of Moldova.
This paper examines how diaspora and local organisations have responded to the crisis in Syria, how they evolved and the challenges that they face - and how international aid organisations and disapora and local groups can better work together in a new aid model.
Part of Comprehensive Primary Health Care
A Formative Evaluation of UNICEF’s Child Protection System Building Approach in Indonesia
At the World Humanitarian Summit in Istanbul in May 2016, leaders made over 3,700 commitments to advance the Agenda for Humanity. In their first self-reports against these commitments, 142 stakeholders described the efforts they made from June to December 2016 to realize this ambitious vision.
The ...2017 annual synthesis report on progress provides a summary of their collective achievements around the 5 Core Responsibilities and 24 Transformations of the Agenda for Humanity.
Executive summary in
English: https://www.agendaforhumanity.org/sites/default/files/asr/2017/Nov/No%20time%20to%20retreat%20Executive%20Summary_NEW_web_nov27.pdf;
French: https://www.agendaforhumanity.org/sites/default/files/asr/2018/Jan/No%20time%20to%20retreat_Executive%20summary_FRENCH_Final_web.pdf
Spanish: https://www.agendaforhumanity.org/sites/default/files/asr/2018/Jan/No%20time%20to%20retreat_Executive%20summary_Spanish_final_web.pdf
more